Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06940154 · ClinicalTrials.gov registry record · Phase 2
Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)
A Phase 2 study of COPD Acute Exacerbation, sponsored by Connect Biopharm.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT06940154 is a Phase 2 study of COPD Acute Exacerbation that is actively recruiting participants, run by Connect Biopharm. The registered enrollment target is 160 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT06940154, a Phase 2 study of COPD Acute Exacerbation, is actively recruiting participants, sponsored by Connect Biopharm.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 2, multicenter study in adult participants with an acute COPD exacerbation and type 2 inflammation
Conditions Studied
Interventions
- COMBINATION_PRODUCT Rademikibart in prefilled syringe
- DRUG Matching placebo in prefilled syringe
Study Locations (20)
Florida
- Synergy Healthcare - Bradenton
- Columbus Clinical Services, LLC - Miami
- Pharmax Research of South Florida, Inc. - Miami
- Health Synergy Clinical Research, LLC - West Palm Beach
Texas
- Inquest Clinical Research - Baytown
- Premier Pulmonary Critical Care and Sleep Medicine - Denison
- DCT- McAllen Primary Care Research, LLC dba Discovery Clinical Trials - McAllen
Georgia
- Primeway Clinical Research Group - Fayetteville
- Pivotal Research Solutions - Stonecrest
Buenos Aires
- CEMER - Centro Medico de Enfermedades Respiratorias - Florida
- Centro de Investigaciones Médicas Mar del Plata - Mar del Plata
Alabama
- University of Alabama at Birmingham Lung Health Center - Birmingham
California
- Amicis Research Center - Valencia
Colorado
- National Jewish Health - Denver
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-08-12 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06940154
The ClinicalTrials.gov registry entry for NCT06940154 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Connect Biopharm, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COPD Acute Exacerbation appearing as the primary indexed condition, and to 2 interventions - of which Rademikibart in prefilled syringe is the first listed.
NCT06940154 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Texas, Georgia.
Frequently Asked Questions
What is clinical trial NCT06940154 about?
NCT06940154 is a clinical study titled "Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD)". This is a Phase 2, multicenter study in adult participants with an acute COPD exacerbation and type 2 inflammation
What is the current status of trial NCT06940154?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2025-08-12. Estimated completion is 2026-05.
What conditions does trial NCT06940154 study?
This clinical trial studies the following conditions: COPD Acute Exacerbation.
What interventions are being tested in trial NCT06940154?
The interventions under investigation include: Rademikibart in prefilled syringe (COMBINATION_PRODUCT), Matching placebo in prefilled syringe (DRUG).
Who is sponsoring clinical trial NCT06940154?
This trial is sponsored by Connect Biopharm, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06940154 being conducted?
This trial has 20 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.